Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative Stress in Elderly
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 60 - 85 |
| Updated: | 5/10/2018 |
| Start Date: | July 2011 |
| End Date: | May 2015 |
The general hypothesis is that elderly have diminished nutritive flow to skeletal muscle and
impaired capacity for building muscle. In aging populations, this decreased ability to build
muscle may represent a tipping point in the progression towards chronic physical frailty and
disability. The goal is to examine whether novel pharmacologic therapies can improve
nutritive blood flow to the muscles and muscle building in the elderly.
The purpose of this study is 1) to determine if losartan administration will enhance blood
flow and 2) to determine if N-acetylcysteine (NAC) will enhance blood flow.
The investigators will study community dwelling, healthy older men and women (60-85 years).
Subjects will be randomized to one of three groups:
Experimental Group 1: Placebo losartan and placebo N-acetylcysteine (NAC). Experimental Group
2: losartan (25mg/dose) and placebo N-acetylcysteine (NAC). Experimental Group 3:
N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo
Subjects will admit to the clinic on day 1 of the study. Baseline testing consisting of leg
blood flow (LBF), contrast enhanced ultrasound, handgrip testing and fatigue questionnaires.
After testing is completed the subjects will recieve their first dose of NAC/ losartan/
placebo with dinner. Subjects will be fasted after 10 pm. On day 2, leg blood flow (LBF) will
be measured approximately 12 hours post dose 1. Subjects will receive their second dose of
NAC/ losartan/ placebo. Leg blood flow will be measured 1 hour and 2 hours post dose 2 of
study interventions. The subjects will eat a meal and receive their third dose of the study
intervention. Leg blood flow will be repeated at 1 hour and 2 hours post dose 3. Appoximately
30 minutes after dose 3 of the study intervention, handgrip testing will be performed and
fatigue questionnaires completed.
impaired capacity for building muscle. In aging populations, this decreased ability to build
muscle may represent a tipping point in the progression towards chronic physical frailty and
disability. The goal is to examine whether novel pharmacologic therapies can improve
nutritive blood flow to the muscles and muscle building in the elderly.
The purpose of this study is 1) to determine if losartan administration will enhance blood
flow and 2) to determine if N-acetylcysteine (NAC) will enhance blood flow.
The investigators will study community dwelling, healthy older men and women (60-85 years).
Subjects will be randomized to one of three groups:
Experimental Group 1: Placebo losartan and placebo N-acetylcysteine (NAC). Experimental Group
2: losartan (25mg/dose) and placebo N-acetylcysteine (NAC). Experimental Group 3:
N-acetylcysteine (NAC) (50 mg/kg/dose) and placebo
Subjects will admit to the clinic on day 1 of the study. Baseline testing consisting of leg
blood flow (LBF), contrast enhanced ultrasound, handgrip testing and fatigue questionnaires.
After testing is completed the subjects will recieve their first dose of NAC/ losartan/
placebo with dinner. Subjects will be fasted after 10 pm. On day 2, leg blood flow (LBF) will
be measured approximately 12 hours post dose 1. Subjects will receive their second dose of
NAC/ losartan/ placebo. Leg blood flow will be measured 1 hour and 2 hours post dose 2 of
study interventions. The subjects will eat a meal and receive their third dose of the study
intervention. Leg blood flow will be repeated at 1 hour and 2 hours post dose 3. Appoximately
30 minutes after dose 3 of the study intervention, handgrip testing will be performed and
fatigue questionnaires completed.
Inclusion Criteria:
1. Age between 60-85 years.
2. Ability to sign informed consent.
3. Ability to sign consent form.
4. Ability to pass a mini-mental status exam (score >23 on the 30-item Mini Mental State
Examination, MMSE).
5. Free-living, prior to admission.
Exclusion Criteria:
1. Subjects with cardiac abnormalities considered exclusionary by the study physicians
(e.g., unstable angina or a cardiology-confirmed ECG that demonstrates cardiac
abnormalities such as > 0.2 mV horizontal or downsloping ST segment depression,
frequent arrhythmia's (> 10 PVC/min), or valvular disease).
2. Subjects with uncontrolled metabolic disease, including liver or renal disease.
3. Subjects with vascular disease characterized by a combination of risk factors of
peripheral atherosclerosis. (e.g., uncontrolled hypertension, obesity, uncontrolled
diabetes, hypercholesterolemia > 250 mg/dl, claudication or evidence of venous or
arterial insufficiency upon palpitation of femoral, popliteal, and pedal arteries.
4. Any history of hypo- or hyper-coagulation disorders. (e.g., Coumadin use or history of
DVT or PE).
5. Subjects with chronically elevated systolic pressure >170 or a diastolic blood
pressure > 100. Subjects may be included if they are taking medication and have a
blood pressure below these criteria.
6. Subjects with cancer or recently (6 months) treated cancer other than basal cell
carcinoma.
7. Any subject currently on a weight-loss diet or a body mass index > 33 kg/m2.
8. Inability to abstain from smoking for duration of study.
9. A history of > 20 pack per year smoking.
10. Subjects with atrial fibrillation, history of syncope, angina, or congestive heart
failure.
11. Any subject that is HIV-seropositive or has active hepatitis.
12. Recent anabolic or corticosteroids use (within 3 months).
13. Subjects with low hemoglobin or hematocrit (i.e., lower than accepted lab values).
14. Agitation/aggression disorder.
15. Dementia.
16. History of stroke with motor disability.
17. A recent history (<12 months) of GI bleed.
18. Alcohol (more than 3 drinks per day) or drug abuse.
19. Polycystic ovary syndrome (PCOS) and/or hyperthecosis.
20. Non-classical adrenal hyperplasia.
21. Cushing's syndrome.
22. Pregnancy.
23. Hyperprolactinoma, hypothyroidism.
24. Lactose intolerance.
25. Subjects with coronary heart or mitral valvular rheumatic heart disease.
26. Subjects with impaired renal function and/or renal artery stenosis.
27. Subjects with pulmonary hypertension.
28. Subjects on any medications known to vasodilate the peripheral arteries.
29. Subjects taking NSAIDs
30. Physical dependence or frailty (impairment of activities of daily living, ADLs).
31. History of falls (>2/year).
32. Depression (>5 of the 15 items on the Geriatric Depression Scale (GDS).
33. Subjects suffering malnutrition or with a BMI < 20 kg/m2 with low albumin or
transferrin.
34. Asthma
35. Any other condition or event considered exclusionary by the PI and covering faculty
physician.
We found this trial at
1
site
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
Click here to add this to my saved trials
